Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Biologics & Nucleic Acid Complex Kundl & Schaftenau by Year
Biologics & Nucleic Acid Complex Kundl & Schaftenau, Austria (m²)
Novartis Biologics & Nucleic Acid Complex Kundl & Schaftenau: 283,017 in FY2025, down 41.0% from a year earlier.
Latest, FY2025
283,017
Period ended Dec 31, 2025
Change on a year earlier
-41.0%
480,000 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Kundl and Schaftenau, Austria | 283 017 | Production of biotechnological products, active drug substances and nucleic acids, drug products and finished products; product development”
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Item 4.D.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biologics & Nucleic Acid Complex Kundl & Schaftenau, Austria (m²) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 283,017 | -41.0% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 480,000 | 0.0% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2023 | Dec 31, 2023 | 480,000 | – | Novartis Form 20-F (0001370368-24-000004) ↗ |
Cite this data
StockData. (2026). Novartis Biologics & Nucleic Acid Complex Kundl & Schaftenau, annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/fac-kundl-m2
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.